Tidal Wave
London, United Kingdom8
750K
7
8.00
0.12
- Stages of investment
- Areas of investment
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 8
- Lead investments
- 0
- Rounds per year
- 8.00
- Follow on index
- 0.12
- Investments by industry
- Software (4)
- Robotics (3)
- Artificial Intelligence (2)
- Aerospace (1)
- Air Transportation (1) Show 14 more
- Investments by region
- United States (7)
- Peak activity year
- 2020
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 4
- Avg. valuation at time of investment
- 1M
- Group Appearance index
- 0.12
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| GPU Audio | 01 Dec 2021 | Software, Music, Musical Instruments | Seed | 6M | United States, California, Los Angeles |
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Hemab Therapeutics | Oct 27, 2025 | Biotechnology, Bleeding and Thrombotic Disorders, Prophylactic Therapeutics | - | 157000000 USD |  Cambridge, Massachusetts |
| Latigo Biotherapeutics | Mar 17, 2025 | Artificial Intelligence, Biotechnology, Nav1.8 inhibitor, Non-opioid pain medicines, Non-opioid Pain Medicines, Non-opioid pain treatments, Pain medicines | - | 150000000 USD | Thousand Oaks, California |
| Andium | Oct 29, 2024 | Emissions Reduction, ESG Monitoring, Industrial Internet of Things, Operational Efficiency, Safety Improvement | Growth stage | 21700000 USD | New York |
| Hemab Therapeutics | Feb 21, 2023 | Biotechnology, Monoclonal and Bispecific Antibody-based Therapeutics, Prophylactic Therapeutics | Growth stage | 135000000 USD |  Copenhagen, |
| Acelyrin | Sep 13, 2022 | Biopharma, Drug Development | Late stage | 300000000 USD | Los Angeles, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.